GSK has received accelerated approval from the US Food and Drug Administration (FDA) for Nelkarmi (neladalkib), a new targeted treatment for adults with previously treated advanced ALK-positive non-small cell lung cancer (NSCLC).
The approval covers patients with locally advanced or metastatic ALK-positive NSCLC whose disease has progressed after treatment with one ALK inhibitor, specifically alectinib, or after two or more ALK inhibitors combined with platinum-based chemotherapy.
The decision is based on results from the Phase 1/2 ALKOVE-1 clinical trial, which evaluated Nelkarmi in patients with advanced ALK-positive cancers. The study showed meaningful and lasting tumour responses in patients who had received previous treatments.
Among patients previously treated with alectinib as their only ALK inhibitor, the confirmed overall response rate was 49%. Of those who responded, 76% maintained their response for at least six months, while 52% continued to respond for 12 months or longer.
In patients who had received two or more ALK inhibitors and platinum-based chemotherapy, the overall response rate was 32%. Among these responders, 69% maintained their response for at least six months and 51% for 12 months or longer.
Nelkarmi is a next-generation, selective ALK tyrosine kinase inhibitor (TKI) designed to address some of the major challenges in ALK-positive lung cancer, including treatment resistance and cancer spreading to the brain. The medicine is also designed to cross the blood-brain barrier and target a broad range of ALK resistance mutations.
The approval comes ahead of the FDA’s original target action date of November 27, 2026. Nelkarmi previously received Breakthrough Therapy and Orphan Drug designations from the agency.
Tony Wood, Chief Scientific Officer at GSK, said the medicine was developed to address important challenges in ALK-positive lung cancer, including resistance to existing treatments and the need for better long-term treatment options.
The approval marks GSK’s second new lung cancer medicine approval in the US in 2026. The company acquired Nelkarmi as part of its acquisition of Nuvalent, completed earlier this year.
GSK is also evaluating Nelkarmi in the ongoing Phase 3 ALKAZAR trial, which is studying the medicine in patients with ALK-positive NSCLC who have not previously received ALK-targeted treatment.
The FDA granted accelerated approval based on tumour response rate and duration of response. Continued approval may depend on the results of a confirmatory clinical trial demonstrating clinical benefit.